Compare VRCA & PMTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VRCA | PMTS |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.3M | 152.4M |
| IPO Year | 2018 | 2015 |
| Metric | VRCA | PMTS |
|---|---|---|
| Price | $6.15 | $17.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $17.00 | ★ $27.67 |
| AVG Volume (30 Days) | ★ 83.8K | 39.9K |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.17 |
| Revenue | $35,577,000.00 | ★ $312,189,000.00 |
| Revenue This Year | N/A | $9.95 |
| Revenue Next Year | $94.44 | $10.02 |
| P/E Ratio | ★ N/A | $93.50 |
| Revenue Growth | ★ 370.22 | 12.27 |
| 52 Week Low | $0.49 | $10.81 |
| 52 Week High | $9.82 | $25.37 |
| Indicator | VRCA | PMTS |
|---|---|---|
| Relative Strength Index (RSI) | 45.71 | 55.22 |
| Support Level | $5.13 | $13.87 |
| Resistance Level | $6.40 | $18.09 |
| Average True Range (ATR) | 0.73 | 1.14 |
| MACD | -0.20 | -0.00 |
| Stochastic Oscillator | 21.52 | 75.26 |
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
CPI Card Group Inc is a payment technology company engaged in providing financial payment card solutions and services. It offers credit, debit, and prepaid cards. The business segments of the group are Debit and Credit, which produces Financial Payment Cards and provides integrated card services to card-issuing banks in the United States, and Prepaid Debit, which provides integrated card services to Prepaid Debit Card program managers in the United States and Others. It derives key revenue from the Debit and Credit segment.